2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents

Int J Mol Sci. 2019 Dec 29;21(1):234. doi: 10.3390/ijms21010234.

Abstract

The ability of 2-deoxy-d-glucose (2-DG) to interfere with d-glucose metabolism demonstrates that nutrient and energy deprivation is an efficient tool to suppress cancer cell growth and survival. Acting as a d-glucose mimic, 2-DG inhibits glycolysis due to formation and intracellular accumulation of 2-deoxy-d-glucose-6-phosphate (2-DG6P), inhibiting the function of hexokinase and glucose-6-phosphate isomerase, and inducing cell death. In addition to glycolysis inhibition, other molecular processes are also affected by 2-DG. Attempts to improve 2-DG's drug-like properties, its role as a potential adjuvant for other chemotherapeutics, and novel 2-DG analogs as promising new anticancer agents are discussed in this review.

Keywords: 2-DG analogs; 2-deoxy-d-glucose; anticancer therapy; glioblastoma.

Publication types

  • Review

MeSH terms

  • Cell Death / drug effects
  • Combined Modality Therapy
  • Deoxyglucose / analogs & derivatives*
  • Deoxyglucose / chemistry
  • Deoxyglucose / pharmacology
  • Deoxyglucose / therapeutic use*
  • Glioblastoma / diagnosis
  • Glioblastoma / drug therapy*
  • Glioblastoma / metabolism
  • Glioblastoma / radiotherapy
  • Glucose / chemistry
  • Glucose / metabolism
  • Glucose-6-Phosphate / metabolism
  • Glucose-6-Phosphate Isomerase / antagonists & inhibitors
  • Glucose-6-Phosphate Isomerase / metabolism
  • Glycolysis / drug effects
  • Hexokinase / metabolism
  • Humans

Substances

  • Glucose-6-Phosphate
  • Deoxyglucose
  • Hexokinase
  • Glucose-6-Phosphate Isomerase
  • Glucose